11 April 2018
US Commercial Operations for BARHEMSYS™ (formerly BAREMSIS®) Expanded Four Key Appointments
Cambridge, UK and Indianapolis, US – 11 April 2018: Acacia Pharma Group plc (“Acacia Pharma”, the “Company” or the “Group”), (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea & vomiting treatments for surgical and cancer patients, has made substantial progress in expanding its US commercial operations for the intended launch of intravenous amisulpride (BAREMSIS®) with four key appointments. The new hires bring significant and relevant commercial experience in launching and marketing hospital pharmaceutical products in the US and have been recruited, as planned, ahead of the target PDUFA date for BAREMSIS of 5 October 2018.
Mike Bolinder, Chief Commercial Officer of the Group’s US subsidiary, Acacia Pharma, Inc., commented: “Filling these key roles with these experienced leaders with such relevant experience provides the Group with a strong foundation for the intended US commercialisation of BAREMSIS. We are delighted to welcome them all to the team and look forward to getting our launch preparations underway. It is a great achievement for Acacia Pharma to attract such high calibre professionals, and to deliver the first key element of our commercialisation strategy so soon after completing our recent Initial Global Offering.”
The new members of Acacia Pharma’s US commercial team are:
Rye Dalton, Vice President of Commercial Operations and Analytics. Rye has over 20 years in the industry and extensive experience in the hospital setting. He has run commercial operations for launches focused on the surgical setting at Otonomy, Inc. for OTIPRIO® and Cadence Pharmaceuticals, Inc. for OFIRMEV® injection for the management of mild to moderate pain.
Jim DiPofi, Vice President of Sales. Jim brings over 28 years of experience in the industry, primarily focused on the hospital market. Jim was recently the VP of Sales at Braeburn Pharmaceuticals, Inc. and previously at Mallinckrodt Pharmaceuticals, Inc. (following its acquisition of Cadence Pharmaceuticals), where he played a key role in the launch success of OFIRMEV.
Shiella Radel, Executive Director of KOL and HCP Marketing Strategy. Shiella has over 30 years’ experience in the industry, primarily in hospital-focused startup companies, and has extensive expertise in communicating with, and meeting the needs of, key opinion leaders (KOLs) and health care practitioners (HCPs). She also joins from Mallinckrodt Pharmaceuticals where she worked with Jim and Rye in delivering the launch and sustained success of OFIRMEV.
James Singell, Executive Director of Marketing Strategy and Operations. James joins from Eli Lilly and Company where he spent more than 25 years in leadership roles covering sales, marketing and new product development and launch in the global, US and key affiliate markets in a broad range of therapeutic areas, including oncology, neuroscience, autoimmune disorders and drug delivery devices.